EEG effects of physostigmine and choline chloride in humans
- PMID: 111288
- DOI: 10.1007/BF00431952
EEG effects of physostigmine and choline chloride in humans
Abstract
Seventeen normal volunteers received either 0.5 mg, 1.5 mg, or 2.5 mg physostigmine i.v. in a placebo-drug-placebo single-blind design. EEG was recorded simultaneously and analyzed by computerized spectral analysis. Eleven healthy elderly volunteers (mean age = 69.1 years) with mild memory impairment were treated with placebo, followed by oral choline chloride (either 8 g/day for 3 weeks, or 16 g/day for 1 week), and then, again, placebo. Recordings of spontaneous EEG and EEG event-related potentials (contingent negative variation) were obtained during both placebo and choline treatments. The larger doses of physostigmine produced an increase in low frequency activity and a slowing of the peak alpha frequency. Oral choline chloride had no effect on the EEG as measured by spectral analysis, but appears to have differential effects on contingent negative variation (CNV) amplitude and reaction time, depending upon the initial CNV amplitude.
Similar articles
-
Choline chloride effects on memory: correlation with the effects of physostigmine.Psychiatry Res. 1980 May;2(2):149-56. doi: 10.1016/0165-1781(80)90071-2. Psychiatry Res. 1980. PMID: 6932060
-
[Ketamine racemate versus S-(+)-ketamine with or without antagonism with physostigmine. A quantitative EEG study on volunteers].Anaesthesist. 1994 Nov;43 Suppl 2:S76-82. Anaesthesist. 1994. PMID: 7840418 Clinical Trial. German.
-
Cholinomimetics and memory. The effect of choline chloride.Arch Neurol. 1980 Jan;37(1):49-52. doi: 10.1001/archneur.1980.00500500079013. Arch Neurol. 1980. PMID: 7350901 Clinical Trial.
-
Human memory and the effects of physostigmine and choline chloride [proceedings].Psychopharmacol Bull. 1980 Oct;16(4):27-8. Psychopharmacol Bull. 1980. PMID: 7454927 No abstract available.
-
Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry.Pharmacopsychiatry. 1987 Feb;20(1 Spec No):12-27. doi: 10.1055/s-2007-1017125. Pharmacopsychiatry. 1987. PMID: 2883677 Clinical Trial.
Cited by
-
Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG.Psychopharmacology (Berl). 1987;93(1):31-5. doi: 10.1007/BF02439583. Psychopharmacology (Berl). 1987. PMID: 3114812 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources